Physician profile
Rukshana N Cader
NPI 1295943660
$3,415.82
in general payments reported to CMS, 2019-2025
18 companies · $441 in 2025
The $441 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.95 · 2020: $457 · 2021: $298 · 2022: $559 · 2023: $1,082 · 2024: $521 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,044.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,044.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,373.49 | 2019-2025 | Skyrizi, Linzess, Viberzi |
| Gilead Sciences, INC. | $488.26 | 2020-2025 | |
| Madrigal Pharmaceuticals | $240.64 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $226.81 | 2019-2024 | Gattex, Eohilia, Entyvio |
| Genzyme Corporation | $162.47 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $151.46 | 2020-2023 | Dificid |
| Celgene Corporation | $139.91 | 2021-2023 | Zeposia |
| Astrazeneca Pharmaceuticals LP | $135.00 | 2023 | Farxiga |
| Regeneron Healthcare Solutions, INC. | $124.33 | 2023 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.11 | 2020-2025 | Xifaxan |
| Ardelyx, INC. | $69.17 | 2023-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $60.29 | 2020-2023 | Ocaliva |
| Pfizer INC. | $33.45 | 2022-2025 | |
| Digestive Care, INC. | $32.73 | 2022-2023 | Pertzye |
| Nestle Healthcare Nutrition INC. | $25.02 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $20.71 | 2020 | |
| Daiichi Sankyo INC. | $18.55 | 2021 | |
| Covidien LP | $16.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rukshana Cader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.